Sumitomo Dainippon Shores Business/Pipeline Ahead Of Latuda Cliff
Facing the looming loss of exclusivity for its top product, Sumitomo Dainippon Pharma is looking to its late-stage pipeline and recent product and corporate acquisitions to help plug the hole.
You may also be interested in...
Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.